Gastroent Hepat Barc
The most recent articles from:
November 2018
-
Gastroent Hepat Barc · Nov 2018
Multicenter Study Observational StudyVedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Vedolizumab (VDZ), a human monoclonal antibody that binds specifically to α4β7-integrin, and is approved for the treatment of Crohn's disease (CD) and ulcerative colitis (UC), has demonstrated its efficacy in controlled clinical trials.